BRAF and melanoma: An in vivo study on nude mice (see Figure 5) demonstrated that the topical administration of Vem-TD-Lip significantly enhanced the antitumor efficacy against melanoma by targeting melanoma cells harboring BRAF mutations and reduced the side effects to major organs compared with both oral and intravenous administration, indicating a higher drug concentration achieved at the melanoma site via the topical route.